Evidence map›Paper›PMID 37545223›Full record

ArticleCancer biomarkers : section A of Disease markers2023

TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.

Tabitha R Hudock, Vayda R Barker, Brandon J Manley, Andrea Chobrutskiy, Boris I Chobrutskiy, Michael J Diaz, Joanna J Song, George Blanck

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tabitha R HudockDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Vayda R BarkerDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Brandon J ManleyDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Andrea ChobrutskiyDepartment of Pediatrics, Oregon Health and Science University Hospital, Portland, OR, USA.
Boris I ChobrutskiyDepartment of Internal Medicine, Oregon Health and Science University Hospital, Portland, OR, USA.
Michael J DiazDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Joanna J SongDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
University of South Florida · USOregon Health and Science University Hospital · USMoffitt Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunogenomics approaches to the characterization of renal cell carcinoma (RCC) have helped to better our understanding of the features of RCC immune dysfunction. However, much is still unknown with regard to specific immune interactions and their impact in the tumor microenvironment.

objectiveThis study applied chemical complementarity scoring for the TRB complementarity determining region-3 (CDR3) amino acid sequences and cancer testis antigens (CTAs) to determine whether such complementarity correlated with survival and the expression of immune marker genes.

methodsTRB recombination reads from RCC tumor samples from RNAseq files obtained from two separate databases, Moffitt Cancer Center and The Cancer Genome Atlas (TCGA), were evaluated. Chemical complementarity scores (CSs) were calculated for TRB CDR3-CTA pairs and survival assessments based on those CSs were performed.

resultsMoffitt Cancer Center and TCGA cases representing the upper 50th percentile of chemical CSs for TRB CDR3 amino acid sequences and the CTA POTEA were found to be associated with a better overall survival (OS) Also, greater tumor RNA expression of multiple immune signature genes, including granzyme A, granzyme B, and interferon-gamma were correlated with the higher chemical CSs.

conclusionsThese results indicate that TRB CDR3-CTA chemical complementarity scoring may be useful in distinguishing RCC cases with a productive, anti-tumor immune response from cases where basic immune parameter assessments are inconsistent with a productive immune response.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsComplementarity Determining RegionsHumansImmunityMaleReceptors, Antigen, T-Cell, alpha-betaTestisTumor MicroenvironmentComplementarity Determining RegionsReceptors, Antigen, T-Cell, alpha-betachemical complementarityimmune signature genesRenal cell carcinomaTRB CDR3 Interactions with cancer testis antigens

Identifiers

PMID37545223
PMCPMC12412846
OpenAlexW4385576957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.